A nanoparticle for delivering an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor to a subject and methods for treating inflamed tissue in a subject using the nanoparticle.
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Inventor
Jovanovic, Goran
Chukwunta, Francis
Coblyn, Matthew
Freiberg, Lucas
Touma, Jad
Baimoldina, Aigerim
Li, Lei
Song, Yihan
Wang, Bingchen
Yang, Fan
Abstract
This disclosure is directed to devices for the separation of mixtures of fluid phases. In some aspects of the disclosure, the separation device comprises an angled capillary cell. In other aspects, the separation device comprises a plurality of angled capillary cells operating in parallel. In some aspects of the disclosure, the separation device may be monolithically formed by an additive manufacturing process, such as three-dimensional printing. In some aspects of the disclosure, the separation device may function independently of gravitational direction, and without the use of filters.
Novel compounds having a thortveitite-related structure are disclosed. The compounds may be colored and may be useful as pigments. The compounds are durable with respect to an acid stability test that indicates that the pigments will not substantially change color when exposed to weak acids, such as rain. The compounds disclosed herein typically inexpensive to synthesize from earth-abundant, environmentally-friendly elements or minerals, and therefore are advantageous over existing pigments in the art.
Disclosed herein is a loading apparatus for restoration and/or cryopreservation of biological materials, a system comprising the same, as well as a method for using the loading apparatus and/or system to restore and/or cryopreserve biological materials. The disclosed loading apparatus and method for using the same focuses on utilizing cycles of applying and removing a load (e.g., tension and/or compression pressure) applied to the biological material that facilitate free-swelling of the biological material back to its natural state without the applied load, wherein the free-swelling promotes dispersion of a cryopreservation agent, therapeutic agent, restoration agent, or a combination thereof throughout the surface area of the biological material.
The United States, as represented by the Secretary of Agriculture, USDA Forest Service (USA)
Inventor
Tinsley, Ryan James
Barbosa, Andre Ramos
Morris, Priscilla
Bean, Jonathan Yorke
Abstract
The present disclosure relates to a structural unit that includes an inner frame having at least one side, an outer frame having at least three sides, and a connecting element, where both the inner frame and the outer frame are positioned parallel to a first reference plane (the xy-plane), the inner frame is positioned within the outer frame, the connecting element physically connects the inner frame and the outer frame, and the connecting element is positioned parallel to the first reference plane.
Briefly, embodiments, such as estimating energy utilization based at least in part on estimated regenerative energy production to select one or more preferred routes for an electric vehicle out of a network of routes, for example, are described.
B60L 53/20 - Methods of charging batteries, specially adapted for electric vehiclesCharging stations or on-board charging equipment thereforExchange of energy storage elements in electric vehicles characterised by converters located in the vehicle
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
9.
REAGENTS AND METHODS FOR BIOORTHOGONAL LABELING OF BIOMOLECULES IN LIVING CELLS
Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and polypeptides having at least one post-translational modification thereof comprising in vivo reaction with the incorporated tetrazine amino acid and a second molecule.
C07D 257/10 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C09B 57/00 - Other synthetic dyes of known constitution
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
10.
Apparatus for Tissue Lysis Under Electromagnetic Field Control
The present invention relates generally to the incorporation of a shroud into an apparatus which achieves tissue and/or cellular disruption through the imposition of a time-varying electromagnetic field generated by electrical means and used to direct magnetic beads or other magnetic particles against a tissue sample. Incorporation of the shroud allows for variation of temperature and/or pressure in the vicinity of the tissue sample during the tissue disruption process.
A machine-learning tool learns from sensors' data of a nuclear reactor at steady state and maps them to controls of the nuclear reactor. The tool learns all given ranges of normal operation and responses for corrective measures. The tool may train another learning tool (or the same tool) that forecasts the behavior of the reactor based on real-time changes (e.g., every 10 seconds). The tool implements an optimization technique for differing half-life materials to be placed in the reactor. The tool maximizes isotope production based on optimal controls of the reactor.
A processing workflow centered on machine-learning algorithms that identifies a number of chemical features that can best distinguish the presence or absence of a chemical source. These chemical features are a chemical fingerprint that is unique to each source. The analysis workflow is rapid (e.g., fingerprints can be generated in minutes). The analysis workflow has wide-ranging applications such as detecting markers of pollution sources in rivers and fish tissues, forest pathogen outbreaks, and hard-to-diagnose diseases.
Systems, devices, and methods are disclosed herein that implement efficient frameworks for Public-Key Infrastructure (PKI) functions. In some implementations of such frameworks, a PKI alliance may comprise multiple, independent certification authorities (CAs), that can coordinate signing operations for digital certificates based on umbrella public keys that a device can use for authentication with any of the CAs. Some embodiments may use multi-party computational thresholding in such signing operations. In other aspects, a device may generate an umbrella public/private key pair, and obtain a digital certificate for the umbrella public key which can be used for efficient network handoffs among CAA members and other secure connections.
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
14.
AUTONOMOUS ORGANISMS FOR SYNTHESIS OF PERMANENTLY PHOSPHORYLATED PROTEINS
Embodiments of the present disclosure provide compositions and methods for biosynthesizing a stable, functional mimic of phosphoserine. The compositions and methods described herein genetically program a host cell to express a biosynthetic pathway that can synthesize the amino acid, 2-amino-4-phosphobobutyric acid, that is a non-hydrolyzable phosphoserine (nhpSer) because it contains a carbon-phosphorus, e.g., phosphonate, bond. In one embodiment the genetically programed cells express the enzymes of a pathway from a Streptomyces bacterium. In some embodiments, nhpSer is translationally incorporated into protein of interest at one or more programmed UAG amber codons using Genetic Code Expansion (GCE) technology.
Clutch assemblies and associated methods are disclosed herein. In an example, a clutch assembly comprise a first terminal, a second terminal, a clutch body enclosing a torque transfer fluid, and one or more electropermanent magnets (EPMs), each configured to generate a respective EPM magnetic field. The clutch assembly is configured to transmit a torque between the first terminal and the second terminal with a torque capacity that is at least partially based on the EPM magnetic fields. In an example, a method of operating a clutch assembly comprises transitioning each of one or more EPMs to a fully depolarized state, a fully polarized state, or an intermediate polarization state. In an example, a method of operating a clutch assembly comprises controlling each of one or more EPMs of the clutch assembly to vary a total EPM magnetic flux generated by the one or more EPMs.
F16D 37/02 - Clutches in which the drive is transmitted through a medium consisting of small particles, e.g. centrifugally speed-responsive the particles being magnetisable
F16D 27/00 - Magnetically-actuated clutchesControl or electric circuits therefor
F16D 27/112 - Magnetically-actuated clutchesControl or electric circuits therefor with an electromagnet not rotating with a clutching member, i.e. without collecting rings with axially movable clutching members with flat friction surfaces, e.g. discs
16.
SCALING-FRIENDLY, ANALOG CORRELATORS USING CHARGE-BASED MARGIN PROPAGATION
A non-multiply-accumulate (non-MAC) charge-based analog correlator system including a sampler circuit block, an operand generation circuit block, and a margin propagation (MP) correlation computation circuit block is disclosed. The sampler circuit block is configured to sample a plurality of input analog signals. The operand generation circuit block is configured to generate operands based on the sampled plurality of input analog signals, and the margin propagation (MP) correlation computation circuit block is configured to generate correlated output signals based on the operands and using calculations in a charge domain.
Embodiments of the present disclosure provide a construct and a method of using the construct to increase the efficiency of Cre-mediated transgene excision. In some embodiments, the construct comprises a cytosine-free lox recombination spacer sequence comprising a nucleotide sequence as set forth in one of SEQ ID NOs: 1-256. In other embodiments, the method is directed to increasing the efficiency of a Cre-mediated transgene excision in a plant cell, the method comprising: (a) introducing into at least one plant cell at least one plasmid comprising at least one cytosine-free lox site; and (b) contacting the at least one cytosine-free free lox site with a Cre recombinase, wherein the transgene is excised more efficiently when the at least one cytosine-free lox site is contacted with the Cre recombinase compared to transgene excision in the absence of the cytosine-free lox site.
A method for making a catalyst comprises providing an initial compound having a perovskite lattice structure according to formula I
A method for making a catalyst comprises providing an initial compound having a perovskite lattice structure according to formula I
M1M2M3O3 FORMULA I,
A method for making a catalyst comprises providing an initial compound having a perovskite lattice structure according to formula I
M1M2M3O3 FORMULA I,
where M1 is about 1 relative elemental ratio strontium (Sr); M2 is from greater than 0 to 0.7 relative elemental ratio and is selected from cobalt (Co), scandium (Sc), iron (Fe), nickel (Ni), and titanium (Ti); and M3 is 0.3 to 0.6 relative elemental ratio iridium (Ir). Initial exemplary compounds include SrSc0.5Ir0.5O3 (SSI) and SrCo0.5Ir0.5O3 (SCI). M1 and/or M2 cations are selectively leached from the initial compound to produce a catalyst having substantially increased catalytic performance. Cycling SSI or SCI in an acid produces SSI-H or SCI-H; cycling SSI or SCI in a base produces SSI-OH or SCI-OH. Dual-site metal leaching induced catalytic activity improvement by about 2 orders of magnitude, making reconstructed SrCo0.5Ir0.5O3 among the best-known catalysts for water oxidation in an acidic condition.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
19.
METHOD AND SYSTEM FOR DETERMINING MATERIAL CONTENT
A wireless sensor network is described. The wireless sensor network comprises an interrogator transceiver operable to transmit a first wireless signal at a first RF frequency and to receive a second wireless signal at a second RF frequency to and from a wireless sensor node embedded within a medium. The medium comprises one or more dielectric materials. The wireless sensor node is interrogatable by the interrogator transceiver. The wireless sensor node is operable to receive the first wireless signal at the first RF frequency from the interrogator transceiver and to transmit the second wireless signal at the second RF frequency to the interrogator transceiver. A processor is coupled to a circuit within the interrogator transceiver. The circuit is operable to measure a power level of a received signal, and the processor is operable to correlate the power level of the received signal to a composition of the medium.
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
20.
PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I or V:
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I or V:
R1—X1—X2—(X3)n—X4—X5—X6—X7—R2 Formula I
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I or V:
R1—X1—X2—(X3)n—X4—X5—X6—X7—R2 Formula I
R1-Asn-Val-Ser-Ala-Tyr-Pro-Thr-R2 Formula V.
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I or V:
R1—X1—X2—(X3)n—X4—X5—X6—X7—R2 Formula I
R1-Asn-Val-Ser-Ala-Tyr-Pro-Thr-R2 Formula V.
Also disclosed are conjugates and compositions comprising the peptides. The compositions may comprise a desired agent to be delivered to the retina, such as a therapeutic agent and/or an imaging agent. Methods for administering the peptide, conjugates, and/or composition to a subject also are disclosed.
Described herein is a magnetic dendrometer having a frame, a spring-tension mechanism, and a magnet for moving together with the spring-tension mechanism. A magnetic sensor is attached to the frame. The magnetic sensor senses the linear motion of the magnet. This linear motion translates to trackable fluctuations in magnetic field. The magnetic fluctuations are converted to electrical signals by the magnetic sensor. A spring is attached to a free-floating wishbone-style component. The free-floating wishbone-style component is couped to a slider which has an adjustable, single-contact point with a target (e.g., a vine, a branch, etc.). The frame is a stationary frame that carries the magnetic sensor. The frame connected via the spring to the wishbone/slider combination cooperates with each other for providing linear motion to extend or contract the spring in length directions. The length variations of the dendrometer spring are converted to linear motion of the magnet and then into electronic signals.
Described herein are methods and pharmaceutical compositions for treating coronavirus-induced disease or preventing infection by a coronavirus by administering an effective amount of a cannabinoid acid or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, to a subject.
Disclosed herein are compounds according to Formula A
Disclosed herein are compounds according to Formula A
Disclosed herein are compounds according to Formula A
wherein the compound comprises at least one C6-30aliphatic moiety. Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some embodiments, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 333/26 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Disclosed is an apparatus and method for fish tagging. In at least one example, the apparatus comprises: a tunnel having a length extending between a first opening and a second opening; a motion sensor positioned on or within the tunnel at a first distance from the first opening, wherein the first distance is a portion of the length; a punch comprising a shaft, wherein the shaft comprises a tip and extends transversely into an interior region of the tunnel through an upper wall of the tunnel at a second distance from the first opening. The punch is coupled to an actuator coupled to the upper wall of the tunnel. and an anvil coupled to a lower wall of the tunnel below the tip of the punch. The anvil comprises a third opening aligned to an axis of the punch.
Cement paste compositions including modified cellulose nanomaterials such as modified cellulose nanocrystals and modified cellulose nanofibers, are disclosed herein. In some embodiments, the cement paste compositions include from about 0.005 volume % to about 1.5 volume % modified cellulose nanomaterial.
Philadelphus variety distinguished by its upright and vigorous, yet compact growth habit, dense branching, deep green foliage late into the season, and prolific flower production.
Hibiscus plant cultivar named ‘ORSTHIB5X1’ is disclosed, characterized by its growth habit and form, deep green foliage that is resistant to chlorosis, seedlessness, and pentaploid chromosome complement.
Embodiments provide for therapeutic agents and methods of use thereof, for treating one or more diseases or conditions. In one example, the therapeutic agent is a lipid nanoparticle comprised of an ionizable lipid, a PEG lipid, a sterol, and a structural lipid, the lipid nanoparticle including one or more mRNA molecules encoding for a soluble form of human angiotensin-converting enzyme 2 and/or variations thereof. In this way, one or more signs or symptoms of Covid-19 may be treated via use of the therapeutic agent.
An metal composite cathode includes a composite of (i) a first component comprising one or more metal salts, wherein each metal salt is an alkali metal salt or an alkaline earth metal salt comprising M where M is Li, Na, K, Mg, Ca, or any combination thereof, (ii) a second component comprising a transition metal, a transition metal sulfide, a transition metal carbonate, a transition metal halide, or any combination thereof, and (iii) a carbon additive. The composite cathode may be used in a metal battery or metal ion battery.
Single cell protein (SCP) is produced by applying a voltage to a microbial electrolysis cell (MEC) under anaerobic conditions for a period of time, whereby SCP is produced. The MEC includes a cathode comprising a hydrogen evolution reaction material, an anode comprising a biofilm on a carbon support, an electrolyte comprising carbon, nitrogen, and phosphorus, and a Methanococcus or Acetobacterium species in the electrolyte.
Described herein is a mismatch shaping technique applied in digital-to-analog converters (DACs) for high pass filtering mismatch related errors. The mismatch shaping scheme is based on a zero mean error encoding technique, which can be applied directly to binary coded signals, without the use for binary to thermometer decoding and element shuffling. In at least one example, an apparatus is provided which comprises a mismatch shaping circuitry to receive an N-bit binary input bits and to generate an (N+1)-bit digital output. In at least one example, the apparatus further comprises a digital-to-analog converter to receive the (N+1)-bit digital output and to generate an analog output, wherein the mismatch shaping circuitry is to encode the (N+1)-bit digital output to shape mismatch errors in the digital-to-analog converter.
Described is a light emitting diode (LED) that uses hybrid nanostructures to enhance light emission intensity and light extraction efficiency. In at least one embodiment, nanostructures comprise a combination of metal and metal oxide layers that simultaneously provide optical property for emission enhancement and support electrical property for charge transport to support electroluminescence. In at least one embodiment, LED comprises multiple layers including a hybrid metal-metal oxide layer, light-emissive layer, and a light outcoupling layer. In at least one embodiment, metal-metal oxide layer can be formed by evaporation or sputtering. In at least one embodiment, light-emissive layer can be formed by emissive layer spin coating. In at least one embodiment, light outcoupling layer is formed by imprinting or by particle lithography.
H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots
Biologically active AhR ligand compounds, and pharmaceutical combinations comprising such compounds, tor treating proliferative cell diseases, such as cancer. Therapeutic combinations also are disclosed that comprise at least one AhR ligand compound together with a synergizing compound that, in combination with the AhR ligand compound, provides a synergistic biological effect. A particularly effective combination according to the present invention comprises (i) BBQ, 10-C1-BBQ and/or 11-C1-BBQ; and (ii) evoxine, citropten, or a combination thereof. Accordingly, the present invention also concerns a method comprising administering a therapeutically effective amount of at least one AhR ligand compound to a subject having a proliferating cell disease. Hie compound may be administered to the subject alone, as a pharmaceutical composition, or as a combination, such as a combination comprising at least one AhR ligand compound and an AhR ligand compound synergizer.
A method for forming graphene-oxide (GO) embedded with gallium-iron alloy (galfenol) nanoparticles. The method includes submerging galfenol bulk material in a solution comprising deionized water and polyvinylpyrrolidone (PVP). The method includes ablating, a first time, the galfenol bulk material submerged in the solution with a laser. The method includes removing the galfenol bulk material from the solution after ablating with the laser. The method includes drying the galfenol bulk material after removing the galfenol bulk material from the solution. The method includes submerging galfenol bulk material in deionized water after drying the galfenol bulk material. The method includes ablating, a second time, the galfenol bulk material submerged in the deionized water and ablating a second time the galfenol bulk material submerged in the deionized water.
C22C 29/12 - Alloys based on carbides, oxides, borides, nitrides or silicides, e.g. cermets, or other metal compounds, e. g. oxynitrides, sulfides based on oxides
Certain disclosed embodiments concern a bioremediation composition comprising microbial cells, at least one co-metabolism substrate to induce selected enzyme production by the microbial cells, and a bead or gel encapsulating the microbial cells, such as bacterial or fungi cells, and the at least one co-metabolism substrate. For certain embodiments, the substrate is a slow release compound, such as an orthosilicate that hydrolyzes to produce an alcohol growth substrate. Embodiments of a method for using the composition to transform contaminants of concern also are disclosed.
Disclosed herein are embodiments of cell culture assays for simultaneous study of chemical and mechanical cues. Also disclosed herein are extracellular matrices for use with the cell culture assays. In some examples, the extracellular matrices can have a textured fibrous structure. Also disclosed herein are embodiments of a modular apparatus for forming the cell culture assays and the extracellular matrices used with the cell culture assays. Methods for using the cell culture assays are also disclosed herein.
Representative xanthohumol derivatives have been made and have been tested in vivo in mice. Such derivatives have a number of important medicinal benefits, including improving glucose tolerance and decreasing weight gain by increasing energy expenditure and locomotor activity in treated subjects. Disclosed derivatives also may function as mitochondrial uncouplers. Representative compounds include 4-(5-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol and 4-(5-(4-hydroxyphenyl)isoxazole-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol.
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
39.
FIBER SUBSTRATE-BASED FLUIDIC ANALYTICAL DEVICES AND METHODS OF MAKING AND USING THE SAME
Embodiments of fiber substrate-based fluidic device and methods of manufacturing the same are described herein. In one example, a microfluidic diagnostic device for detecting a presence and/or concentration of an analyte includes a nitrocellulose substrate sandwiched between two bonded layers of a hydrophobic film. The nitrocellulose substrate includes a plurality of wells and/or fluidic channels formed in the nitrocellulose substrate such that boundaries of the wells and/or fluidic channels are defined by the nitrocellulose and at least one of the bonded layers of the hydrophobic film.
The present disclosure describes probiotic compositions comprising Emergencia timonensis and methods for using probiotic compositions comprising Emergencia timonensis to reducing TMA and/or TMAO levels in subjects in need thereof.
Disclosed herein is a method for making a quaternary ammonium salt according to the formula
Disclosed herein is a method for making a quaternary ammonium salt according to the formula
Disclosed herein is a method for making a quaternary ammonium salt according to the formula
Also disclosed is a method for making the ammonium salts from an oleofuran compound. The compounds are useful as antibacterial and/or antiviral compounds and methods for administering the compounds also are disclosed.
Disclosed is a synthetic gene cluster for producing gadusol derivatives, expression vectors and host cells containing the same, methods of producing gadusol derivatives, and compositions thereof. In an example, the synthetic gene cluster includes a valA nucleotide sequence capable of expressing ValA protein; a nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein; a mysC nucleotide sequence capable of expressing a MysC protein; and a mysD nucleotide sequence capable of expressing a MysD protein. In this way, gadusol derivatives can be produced in amounts sufficient for use in a variety of applications.
Certain disclosed embodiments concern an organic solution suitable for forming metal oxide films, particularly thins films, comprising a metal salt selected from a Sn salt, an Sb salt, a dopant, and combinations thereof. The salt often is a halide salt, such as SnCl2 or SbCl3. Certain disclosed compositions are preferably formed using substantially pure reagents and may include a dopant, such as a fluoride dopant. Described solutions may be used to form thin films, such as a thin film comprising SnO2, Sb:SnO2, F:SnO2, or (Sb,F):SnO2. Such thin films may have any desired thickness, such as a thickness of from 200 or 700 nm, and are extremely smooth, such as having an RMS surface roughness >3 nm, such as 3 nm to 10 nm, with certain embodiments having an RMS surface roughness <2 nm or <1 nm. Devices can be assembled comprising the thin films on a suitable substrate.
C23C 18/12 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by thermal decomposition characterised by the deposition of inorganic material other than metallic material
44.
ELECTROCATALYTIC POLYMER DEVICE FOR BIOLOGICAL DETECTION
Disclosed herein is an electrochemical biosensor comprising at least one working electrode on an electrically insulative substrate. At least one working electrode incorporates an electrocatalytic film, comprising a molecularly imprinted polymer (MIP) layer. In at least one embodiment, MIP layer comprises a plurality of shape-selective cavities and a plurality of non-biological electrocatalytic centers.
Various embodiments of a magneto-acoustic spin-wave signal processing system are provided. In one embodiment, a system includes an acoustic wave transducer configured to produce surface acoustic waves in a plane of a magnetostrictive material, wherein the magnetostrictive material serves as a medium for spin waves traveling in the plane, and wherein the acoustic wave transducer is oriented such that the acoustic waves parametrically amplify the spin waves. In this way, signal processing systems achieve the benefits of both spin wave and acoustic wave devices, taking advantage of the low dispersion and high dynamic range of acoustic waves coupled with the tunability and nonlinear effects provided by spin waves.
Novel compounds having a thortveitite-related structure are disclosed. The compounds may be colored and may be useful as pigments. The compounds are durable with respect to an acid stability test that indicates that the pigments will not substantially change color when exposed to weak acids, such as rain. The compounds disclosed herein typically inexpensive to synthesize from earth-abundant, environmentally-friendly elements or minerals, and therefore are advantageous over existing pigments in the art.
Disclosed herein are embodiments of a nanoparticle suitable for use in providing hyperthermia treatment. The nanoparticle may be a cobalt-doped iron oxide nanoparticle. Also disclosed are compositions comprising the nanoparticle. The composition may further comprise a polymer and/or a targeting moiety. Further disclosed and methods for making the nanoparticle and the composition, and embodiments of a method for using the nanoparticle or a composition thereof. The nanoparticle may be useful for treating cancer, and/or endometriosis.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
48.
SMALL MOLECULE ENHANCERS OF ANTISENSE OLIGO ACTIVITY
Methods and compositions for the cytosolic delivery of bioactive macromolecules. In the methods, an effective amount of an enhancer molecule is used to facilitate the cytosolic delivery of the bioactive macromolecule.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
Described herein is a technique (e.g., apparatus and method) to improve consistency of lumbar lordosis (LL) and disc height index (DHI) measurements. In at least one embodiment, one or more processors are to measure lumber spine based, at least in part, on cross-sectional area and optical center of mass of segmented intervertebral discs (IVDs).
Embodiments of the claimed invention describe methods for making a multimeric nanobody assembly. In some embodiments, a method for making a multimeric nanobody assembly comprises providing polynucleic acids that encode for nanobodies, wherein the polynucleic acids each further comprise at least one selector codon at a preselected position, providing a non-peptide linker comprising a strained alkene functional group, and providing a translational system, wherein the polynucleic acids are translated by the translational system to encode the nanobodies, and wherein the tetrazine amino acids react with the strained alkene functional group to produce the multimeric nanobody assembly.
The present invention provides in certain embodiments comprising a pyrrolysine- based aminoacyl -tRN A synthetase and a tRNA to form a pyrrolysine-based aminoacyl-tRNA synthetase/tRNA pair. The present invention also provides novel pyrrolysine-based aminoacyl-tRNA synthetases, cells and compositions comprising pyrrolysine-based aminoacyl-tRNA synthetases. The present invention also provides methods of using these pyrrolysine-based aminoacyl-tRNA synthetases.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (USA)
Inventor
Sikora, Aleksandra E.
Zielke, Ryszard A.
Jerse, Ann E.
Abstract
Methods are disclosed for inducing an immune response to Neisseria gonorrhoeae in a mammalian subject. These methods include administering to the mammalian subject an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide, thereby inducing the immune response. Also disclosed are immunogenic compositions including an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide.
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
OREGON STATE UNIVERSITY (USA)
Inventor
Yokota, Toshifumi
Yokota-Maruyama, Rika
Moulton, Hong M.
Abstract
The present disclosure relates generally to DG9 peptide-conjugated splice modulating therapies for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
54.
ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS
Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
The U.S.A., as Represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Moulton, Hong M.
Stein, David Adam
Feldmann, Heinrich Ulrich
Rosenke, Kyle Ture
Abstract
Disclosed herein are embodiments of a compound useful for treating or preventing betacoronavirus infections such as SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a betacoronavirus infection in the subject. The compound can comprise an oligomer comprising a nucleic acid base sequence that is antisense to at least a portion of a SARS-CoV-2 genomic RNA, and can comprise a sequence present in the 5′ UTR and first 20 nt of coding sequence of the SARS-CoV-2 genomic RNA. The compound also can contain a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
56.
PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA
Disclosed herein are peptides useful for targeting the retina, and may be useful for targeting specific cells in the retina. The peptides may have a Formula I: R1123n45677-R2or a formula V: R1-Asn-Val-Ser-Ala-Tyr-Pro-Thr-R2. Also disclosed are conjugates and compositions comprising the peptides. The compositions may comprise a desired agent to be delivered to the retina, such as a therapeutic agent and/or an imaging agent. Methods for administering the peptide, conjugates, and/or composition to a subject also are disclosed.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
57.
Semiconductor circuits and devices based on low-energy consumption semiconductor structures exhibiting multi-valued magnetoelectric spin hall effect
A semiconductor device includes ferromagnetic, magnetostrictive layer that exhibits a biaxial magnetic anisotropy and an underlying structure exhibits a spin Hall effect to provide a conversion between electrical energy and magnetic energy with more than two distinctive magnetic states, wherein the underlying structure includes a piezoelectric material structure and a spin Hall metal layer.
G11C 16/04 - Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS
G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
G11C 11/18 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using Hall-effect devices
G11C 11/56 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using storage elements with more than two stable states represented by steps, e.g. of voltage, current, phase, frequency
A method for making a catalyst comprises providing an initial compound having a perovskite lattice structure according to formula (I) M1M2M33, 3, where M1is about 1 relative elemental ratio strontium (Sr); M2is from greater than 0 to 0.7 relative elemental ratio and is selected from cobalt (Co), scandium (Sc), iron (Fe), nickel (Ni), and titanium (Ti); and M30.50.530.50.533 (SCI). M1and/or M20.50.533 among the best-known catalysts for water oxidation in an acidic condition.
Described herein is a magnetic dendrometer having a frame, a spring-tension mechanism, and a magnet for moving together with the spring-tension mechanism. A magnetic sensor is attached to the frame. The magnetic sensor senses the linear motion of the magnet. This linear motion translates to trackable fluctuations in magnetic field. The magnetic fluctuations are converted to electrical signals by the magnetic sensor. A spring is attached to a free-floating wishbone-style component. The free-floating wishbone-style component is coupled to a slider which has an adjustable, single-contact point with a target (e.g., a vine, a branch, etc.). The frame is a stationary frame that carries the magnetic sensor. The frame connected via the spring to the wishbone/slider combination cooperates with each other for providing linear motion to extend or contract the spring in length directions. The length variations of the dendrometer spring are converted to linear motion of the magnet and then into electronic signals.
Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A wireless communication system includes memory configured to store a model for predicting one or more parameters of the system, and one or more processors configured to: receive samples of the wireless communication system over a plurality of sequential batches, each of the batches represents a different, non-overlapping period of time; for each of the batches: select, based on a sample selection criteria, a subset of the samples from a first batch as representative samples for the first batch, wherein the sample selection criteria is based on a system performance metric computed for each of the samples; store the subset of the samples for one or more of the sequential batches in the memory; and upon receiving samples for a second batch, train the model to predict the one or more parameters using the samples from the second batch and the subset of the samples stored in the memory.
A retinomorphic sensor is demonstrated employing organic semiconductors. The sensor produces an output voltage in response to changes in illumination, but zero output voltage under constant illumination. The device is stable for periods up to one hour, exhibits a decay constant tunable through choice of external resistor, with fastest response times below 10 μs.
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
63.
SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS
Methods for inducing growth inhibition or apoptosis of Bcl-2-expressing cells and treatments of Bcl-2 expressing cancers are provided. Additionally, assays for agents that can induce apoptosis of Bcl-2 expressing cells are disclosed.
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
64.
Compositions and methods for enhanced production of enduracidin in a genetically engineered strain of streptomyces fungicidicus
C07K 14/36 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from ActinomycesPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptomyces (G)
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
with a compound according to formula II
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
with a compound according to formula II
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
with a compound according to formula II
in the presence of a Lewis acid to form a phenol compound according to formula III and/or a benzofuranone compound according to formula IV
Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I
with a compound according to formula II
in the presence of a Lewis acid to form a phenol compound according to formula III and/or a benzofuranone compound according to formula IV
C07C 37/07 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
Compositions comprising RqSnOm(OH)x(HCO3)y(CO3)z are disclosed, where R is (i) C1—C10 hydrocarbyl or (ii) heteroaliphatic, heteroaryl, or heteroaryl-aliphatic including 1-10 carbon atoms and one or more heteroatoms; q = 0.1-1; x ≤ 4; y ≤ 4; z ≤ 2; m = 2 - q/2 - x/2 - y/2 - z; and (q/2 + x/2 + y/2 + z) ≤ 2 Methods of making a photoresist film comprising [(RSn)12O14(OH)6](OH)2 on a substrate also are disclosed. The photoresist film may be irradiated to form RqSnOm(OH)x(HCO3)y(CO3)z.
Disclosed herein are compounds according to Formula (A) wherein the compound comprises at least one C6-30aliphatic moiety. Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some embodiments, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
C07D 333/26 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A computer implemented scheme for a light detection and ranging (LIDAR) system where point cloud feature extraction and segmentation by efficiently is achieved by: (1) data structuring; (2) edge detection; and (3) region growing.
6-306-30aliphatic moiety. Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some embodiments, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
C07D 333/26 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present disclosure provides a method for preparing a supported metal alloy catalyst for low temperature engine exhaust oxidation without CO or NO inhibition. The catalyst includes bimetallic PdCu alloy deposited on a SiO2 support using the strong electrostatic adsorption method. The PdCu catalyst may be combined with a traditional PGM-based automotive oxidation catalyst in a series or dual-bed configuration. The first stage of the dual-bed system includes the PdCu catalyst, with the primary role of oxidizing CO at low temperature; the PGM-based catalyst in the second stage then oxidizes NO and hydrocarbons in the absence of any CO-inhibition effects.
B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
e.gStreptomycesStreptomyces bacterium. In some embodiments, nhpSer is translationally incorporated into a protein of interest at one or more programmed UAG amber codons using Genetic Code Expansion (GCE) technology.
Disclosed herein are embodiments of a nanoparticle composition suitable for delivering a therapeutic agent to a subject by nebulization. The nanoparticle comprises an ionizable lipid, cholesterol or a derivative thereof, a structural lipid, and a PEG lipid. The nanoparticle may partially or completely encapsulate a therapeutic agent, and may be nebulized for administration, such as by inhalation. In some embodiments, the therapeutic agent is mRNA.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 9/00 - Medicinal preparations characterised by special physical form
A print head comprising nested chambers for in-situ reactant formation is disclosed. The print head comprises a first chamber nested within a second chamber. The first chamber comprises a first nozzle, the second chamber comprises a second nozzle. The first nozzle is substantially coaxial with the second nozzle. A susceptor to convert electromagnetic energy to heat is within the first chamber. The susceptor comprises one or more openings extending between the upper portion and the lower portion. The susceptor may be heated by induction heating or by optical heating to vaporize a precursor substance within the first chamber. The vapor may react with a reactive gas flowing through the first chamber or expand through a nozzle into a second chamber where the vapor may react with the reactive gas, forming nanoparticles. Patterned films may be written onto a two-dimensional or three-dimensional surfaces.
B05B 1/28 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means with integral means for shielding the discharged liquid or other fluent material, e.g. to limit area of sprayNozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means with integral means for catching drips or collecting surplus liquid or other fluent material
B05B 7/00 - Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
74.
METHOD FOR RECYCLING POLYVINYL CHLORIDE (PVC) TO PRODUCE HIGH DENSITY POLYETHYLENE (HDPE)
Disclosed herein is a process to convert PVC plastic into a dechlorinated polymer, such as high density polyethylene, while substantially avoiding carbonization. The process also facilitates Cl recovery and/or reintroducing the dechlorinated plastic into product streams. In some embodiments, the process comprises heating a mixture of PVC and a catalyst and/or a base in a solvent, optionally in the presence of hydrogen gas.
C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
C08F 4/80 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from iron group metals or platinum group metals
75.
METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION WITH CANNABINOID ACIDS
Described herein are methods and pharmaceutical compositions for treating coronavirus-induced disease or preventing infection by a coronavirus by administering an effective amount of a cannabinoid acid or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, to a subject.
A system to mechanically test specimen including a device testing unit subassembly, a first marker assembly, and a second marker assembly. A first gripping assembly and a second gripping assembly are in a space apart orientation along an axis, and respectively are structurally configured to retain a test specimen and to facilitate the imparting of stress and/or strain thereto. The first marker assembly is associated with the first gripping assembly and has a first rod extending from the first grip with a marker attached thereto. The second marker has a second rod extending from the second grip a marker attached thereto. The first and second markers comprise an X-ray opaque material. Additionally, a method of use is disclosed.
This disclosure concerns a system and a method for removing dissolved solids from liquids. Specific implementations concern desalinating water. The system may comprise a blower, such as a thermal fan/compressor, configured to atomize a solid-bearing liquid to produce a hot, humid gas containing dissolved solids; a gas-solid separator configured to receive hot, humid gas containing entrained dissolved solids from the blower to separate the solids from the humid gas and to transmit the humid gas with solids removed through an exit port; a heater configured to heat the hot, humid gas received from the exit port of the gas-solid separator; and a condenser configured to receive heated humid gas from the heater and to condense solids-free liquid therefrom. The thermal fan/compressor may comprise a plurality of nozzles with outlets positioned adjacent atomization apertures across which a solid-bearing liquid flows and through which gas exiting the nozzles passes.
B01D 45/16 - Separating dispersed particles from gases or vapours by gravity, inertia, or centrifugal forces by centrifugal forces generated by the winding course of the gas stream
B01D 5/00 - Condensation of vapoursRecovering volatile solvents by condensation
B01D 1/14 - Evaporating with heated gases or vapours in contact with the liquid
C02F 1/10 - Treatment of water, waste water, or sewage by heating by distillation or evaporation by direct contact with a particulate solid or with a fluid, as a heat transfer medium
C02F 1/14 - Treatment of water, waste water, or sewage by heating by distillation or evaporation using solar energy
C02F 1/04 - Treatment of water, waste water, or sewage by heating by distillation or evaporation
F04F 5/18 - Jet pumps, i.e. devices in which fluid flow is induced by pressure drop caused by velocity of another fluid flow the inducing fluid being elastic fluid displacing elastic fluids for compressing
Disclosed probes comprise metal nanoparticle cores associated with magnetic particles that allow probes associated with targets to be concentrated by an applied magnetic field to increase detection sensitivity and provide sufficient spacing between concentrated probes to avoid signal quenching. The probe may comprise at least one recognition receptor, and may further comprise at least one reporter molecule, such as a fluorescent tag, a Raman reporter, or combinations thereof. Concentrating probe-target composites substantially enhances a sensing signal, such as from 5 to 10 times, compared to detection without concentrating the probes. The method may be used to detect, for example, interleukins at concentrations at least as low as 25 pg/ml in sputum or blood from a subject for early and precise profiling of viral infections, such as SARS-CoV-2 infections.
Disclosed herein is a method for making a quaternary ammonium salt according to the formula Also disclosed is a method for making the ammonium salts from an oleofuran compound. The compounds are useful as antibacterial and/or antiviral compounds and methods for administering the compounds also are disclosed.
C07D 307/34 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 307/46 - Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
Embodiments provide for therapeutic agents and methods of use thereof, for treating one or more diseases or conditions. In one example, the therapeutic agent is a lipid nanoparticle comprised of an ionizable lipid, a PEG lipid, a sterol, and a structural lipid, the lipid nanoparticle including one or more mRNA molecules encoding for a soluble form of human angiotensin-converting enzyme 2 and/or variations thereof. In this way, one or more signs or symptoms of Covid-19 may be treated via use of the therapeutic agent.
Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.
C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 209/12 - Radicals substituted by oxygen atoms
C07D 307/80 - Radicals substituted by oxygen atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
82.
XANTHOHUMOL DERIVATIVES AND METHODS FOR MAKING AND USING
in vivo in vivo in mice. Such derivatives have a number of important medicinal benefits, including improving glucose tolerance and decreasing weight gain by increasing energy expenditure and locomotor activity in treated subjects. Disclosed derivatives also may function as mitochondrial uncouplers. Representative compounds include 4-(5-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol and 4-(5-(4-hydroxyphenyl)isoxazole-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol.
A general-purpose approach to solving the core problems of detecting and predicting the actions of invisible actors, and the consequential challenges of intervention and prevention. The operational forecasting system is applied to data gathered from complex systems. The operational forecasting system uses novel early-warning signals that are based on anomalous behaviors of actors/agents that are observed, as they respond to those unobserved actors that are the source of systemic change. The operational forecasting system targets predicting when an event will occur, before it does, based on the anomalous behaviors of observed actors responding to those invisible actors that are creating the perturbation (i.e. the murmuration).
An ultraviolet radiation-curable composition comprising a polyester having at least one pendant ultraviolet radiation-curable moiety covalently bonded to the polyester, wherein the polyester does not contain any free-radically polymerizable activated C═C groups.
C09J 167/00 - Adhesives based on polyesters obtained by reactions forming a carboxylic ester link in the main chainAdhesives based on derivatives of such polymers
85.
ANTIBIOTIC POTENTIATION FOR NONTUBERCULOUS MYCOBACTERIAL DISEASE
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
86.
MICRO-LED APPARATUS WITH A SERIES OF CARBON-BASED LIGHT-EMITTING MATERIALS AND MANUFACTURING METHOD FOR ADJUSTING EMISSION COLORS
Disclosed herein are materials and a micro-LED display with carbon-based light-emitting materials, carbon quantum dots, that are made by a solvothermal synthesis of a mixture of aromatic amino acid, 3,4-dihydroxy-L-phenylalanine (LDOPA), and urea in dimethylformamide (DMF). The mixture is heated in a sealed pressure reactor at a temperature, ranging from 120 degrees Celsius to 350 degrees Celsius, for 4-24 hours. The product is then purified to collect the solid powder. The purified CDs can be dissolved in an acrylate monomer solution or a polymer solution for material delivery and curing process on a target substrate for the applications, including light-emitting devices or sensors.
A plant cuticle supplement comprising a cellulose component, one or more oils comprising medium or long chain fatty acids, one or more surfactants, a protic organic solvent, and potassium bentonite. An aqueous composition comprising the plant cuticle supplement and methods of reducing water consumption by a plant and methods for method of reducing egg laying of D. suzukii on a plant using the aqueous composition.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 25/22 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
88.
Nano-cellulose coatings to prevent damage in foodstuffs
Disclosed herein are embodiments of a composition for use in forming films or coatings that prevent damage in foodstuffs, including plants, fruits, and vegetables. The disclosed compositions comprise a cellulose nanomaterial and can further comprise a nanoscale mineral compound and one or more additional components. Also disclosed are films or coatings made using the disclosed compositions, as well as methods for making the disclosed compositions and methods for using the disclosed compositions.
C07C 251/80 - Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
Board of Regents, The University of Texas System (USA)
Oregon State University (USA)
Inventor
Greenberg, David
Geller, Bruce L.
Abstract
Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are embodiments of a composition comprising at least one cellulose material (such as a cellulose nanomaterial) and an optional inorganic salt component. Some embodiments of the composition can further comprise additional components, with some embodiments further comprising a non-starch polysaccharide (e.g., methyl cellulose carboxymethyl cellulose or other cellulose derivative, chitosan, or the like), a surfactant, a plasticizer, an antimicrobial component, or any combination thereof. The disclosed compositions are useful for forming edible coatings/films on plants, plant parts, and other objects. The disclosed compositions and coatings/films made using the compositions are effective at protecting fresh and processed produce and other substances and products, from various different types of food processing damage (and the deleterious effects associated therewith).
A scheme for identifying wireless devices by capturing out-of-band information in addition to in-band information from wireless devices for enabling accurate classification of wireless devices. Both the in-band and out-of-band spectrum emissions of the received signal are used to capture hardware signatures and features. These hardware signatures are used to discriminate different wireless devices uniquely and efficiently, even when the devices have the same hardware with significantly reduced distortions. The out-of-band information can be extracted using radios with software defined capabilities. Deep learning-based device classification technique is applied that uses IQ samples collected from the RF signals to efficiently identify and classify high-performing transmitters that have the same, minimally distorted hardware components.
Reagents and aqueous solutions thereof are described that are useful for aqueous processing to form thin films comprising metal oxides. A film, or layered film, may be incorporated into working devices where the thin film provides useful optical properties, electrical properties, or both.
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
H01L 51/52 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED) - Details of devices
H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof
95.
Fiber substrate-based fluidic analytical devices and methods of making and using the same
Embodiments of fiber substrate-based fluidic device and methods of manufacturing the same are described herein. In one example, a method of manufacturing a fiber substrate-based fluidic device comprises bonding a hydrophobic film that is substantially transparent to a laser beam (e.g., a film that transmits at least 80% of the incident radiant power of the laser beam) to a hydrophilic substrate and ablating the hydrophilic substrate with the laser beam without ablating the hydrophobic film to form one or more fluidly sealed channels in the hydrophilic substrate.
A method is provided to reduce the counting times in radiation detection systems using machine learning, wherein the method comprises: receiving output data from a detector which is to detect a target material from a target body; analyzing the output data; identifying a material of interest from the analyzed output data; and controlling a source of the target material to prevent the source from harming the target body. An apparatus is also provided which comprises: a detector to detect radiation and to provide an output data in real-time; and a processor coupled to the detector, wherein the processor is to: receive the output data; analyze the output data; identify a material of interest from the analyzed output data; and control a source of the target material.
Cu-based bulk amorphous alloys in the quaternary Cu—Zr—Hf—Al alloy system are disclosed. A method of casting such alloys and articles comprising such alloys also are disclosed.
C22C 45/10 - Amorphous alloys with molybdenum, tungsten, niobium, tantalum, titanium, or zirconium as the major constituent
B22D 21/00 - Casting non-ferrous metals or metallic compounds so far as their metallurgical properties are of importance for the casting procedureSelection of compositions therefor
98.
Slewing mitigation apparatus for switched capacitor circuit
A slewing mitigation technique is presented where just the right amount of charge is provided at the switching instant to a switch capacitor circuit so that operational transconductance amplifier (OTA) does not need to provide high peak current. This eliminates slewing altogether and allows using OTAs with less static current for the same settling accuracy.
A pressure sensitive adhesive construct comprising:
(A) a backing substrate; and
(B) a pressure sensitive adhesive composition disposed on the backing substrate, wherein the pressure sensitive adhesive composition includes an ultraviolet radiation-cured polymer made from:
(a) at least one epoxidized plant oil, at least one epoxidized animal fat, or a mixture thereof;
(b) at least one dicarboxylic acid, at least one polycarboxylic acid, or a mixture thereof; and
(c) at least one compound that contains both one carbon-carbon double bond (C═C) and at least one carboxylic acid group.
C09J 191/00 - Adhesives based on oils, fats or waxesAdhesives based on derivatives thereof
C08G 59/16 - Polycondensates modified by chemical after-treatment by monocarboxylic acids or by anhydrides, halides or low-molecular-weight esters thereof
100.
Analogues and derivatives of cephalotaxine and methods for making and using the compounds
Disclosed herein are embodiments of a compound having a Formula I
or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof.
Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.
C07D 491/153 - Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
